•
Mar 31, 2020

Novocure Q1 2020 Earnings Report

Reported revenue growth and financial strength, clinical pipeline developments and the company’s response to COVID-19.

Key Takeaways

Novocure reported a strong quarter with $102 million in net revenues, $4 million in net income, and $331 million cash on hand. Net revenues increased by 39% compared to the first quarter 2019.

Net revenues of $101.8 million, representing 39 percent growth versus the first quarter 2019.

Gross profit of $77.3 million, a 45% increase compared to Q1 2019.

Net income of $4.0 million compared to a net loss of $12.2 million for the same period in 2019.

Cash, cash equivalents and short-term investments at end of period $331.3 million, a 29% increase compared to Q1 2019.

Total Revenue
$102M
Previous year: $73.3M
+38.9%
EPS
$0.04
Previous year: -$0.13
-130.8%
Active Patients
3.1K
Previous year: 2.63K
+17.6%
Prescriptions Received
1.41K
Previous year: 1.31K
+7.6%
Gross Profit
$77.3M
Previous year: $53.5M
+44.5%
Cash and Equivalents
$182M
Previous year: $152M
+19.6%
Free Cash Flow
-$1.16M
Previous year: -$6.64M
-82.6%
Total Assets
$502M
Previous year: $370M
+35.7%

Novocure

Novocure

Forward Guidance

Novocure continues to advance its clinical milestones with data readouts expected over the next several years.